Who makes B: BI 10773 tablet and metformin tablet?

B: BI 10773 tablet and metformin tablet is developed by Boehringer Ingelheim.

What development phase is B: BI 10773 tablet and metformin tablet in?

B: BI 10773 tablet and metformin tablet is in Phase 1.

What are the side effects of B: BI 10773 tablet and metformin tablet?

Common side effects include White blood cells in urine, Hyperglycaemia, Headache.

Last reviewed 2026-04-20 · How we verify

B: BI 10773 tablet and metformin tablet

Boehringer Ingelheim · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	B: BI 10773 tablet and metformin tablet
Sponsor	Boehringer Ingelheim
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

White blood cells in urine
Hyperglycaemia
Headache

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

B: BI 10773 tablet and metformin tablet CI brief — competitive landscape report
B: BI 10773 tablet and metformin tablet updates RSS · CI watch RSS
Boehringer Ingelheim portfolio CI